Gaucher disease: resetting the clinical and scientific agenda

Am J Hematol. 2009 Apr;84(4):205-7. doi: 10.1002/ajh.21384.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Adult
  • Child
  • Gaucher Disease / complications
  • Gaucher Disease / drug therapy*
  • Gaucher Disease / enzymology
  • Gaucher Disease / ethnology
  • Gaucher Disease / genetics
  • Gaucher Disease / immunology
  • Genetic Heterogeneity
  • Genetic Predisposition to Disease
  • Glucosylceramidase / administration & dosage
  • Glucosylceramidase / adverse effects*
  • Glucosylceramidase / deficiency
  • Glucosylceramidase / genetics
  • Glucosylceramidase / therapeutic use
  • Glucosylceramides / blood
  • Humans
  • Hypertension, Pulmonary / chemically induced
  • Hypertension, Pulmonary / epidemiology
  • Hypertension, Pulmonary / etiology
  • Jews / genetics
  • Models, Immunological
  • Multiple Myeloma / epidemiology
  • Multiple Myeloma / etiology
  • Multiple Myeloma / genetics
  • Mutation
  • Neoplasms / chemically induced
  • Neoplasms / epidemiology
  • Neoplasms / etiology*
  • Neoplasms / genetics
  • Prevalence
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / adverse effects
  • Recombinant Proteins / therapeutic use
  • Registries / statistics & numerical data
  • Risk
  • Selection, Genetic
  • Unnecessary Procedures

Substances

  • Glucosylceramides
  • Recombinant Proteins
  • Glucosylceramidase
  • imiglucerase